{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:47:20Z","timestamp":1782564440818,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82302898"],"award-info":[{"award-number":["82302898"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12115-z","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:11:52Z","timestamp":1782562312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Filgotinib induces apoptosis in colorectal cancer cells by activating the p53 signaling pathway"],"prefix":"10.1007","volume":"53","author":[{"given":"Ying","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenmeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"3","key":"12115_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. Cancer J Clin 71(3):209\u2013249","journal-title":"Cancer J Clin"},{"issue":"9","key":"12115_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2174\/18735592MTEx9NTk2y","volume":"22","author":"F Baidoun","year":"2021","unstructured":"Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT et al (2021) Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets 22(9):998\u20131009","journal-title":"Curr Drug Targets"},{"issue":"10207","key":"12115_CR3","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/S0140-6736(19)32319-0","volume":"394","author":"E Dekker","year":"2019","unstructured":"Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet (London England) 394(10207):1467\u20131480","journal-title":"Lancet (London England)"},{"issue":"15","key":"12115_CR4","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","volume":"329","author":"J Watanabe","year":"2023","unstructured":"Watanabe J, Muro K, Shitara K, Yamazaki K, Shiozawa M, Ohori H et al (2023) Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, left-sided metastatic colorectal cancer: a randomized clinical trial. JAMA 329(15):1271\u20131282","journal-title":"JAMA"},{"issue":"1","key":"12115_CR5","doi-asserted-by":"publisher","first-page":"10217","DOI":"10.1038\/s41467-024-54460-2","volume":"15","author":"M Shiozawa","year":"2024","unstructured":"Shiozawa M, Sunakawa Y, Watanabe T, Ota H, Yasui H, Yabuno T et al (2024) Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trial. Nat Commun 15(1):10217","journal-title":"Nat Commun"},{"issue":"2","key":"12115_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.soc.2021.11.006","volume":"31","author":"S Sakata","year":"2022","unstructured":"Sakata S, Larson DW (2022) Targeted therapy for colorectal cancer. Surg Oncol Clin N Am 31(2):255\u2013264","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"12115_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1158\/2159-8290.CD-20-0142","volume":"11","author":"MH Hofmann","year":"2021","unstructured":"Hofmann MH, Gmachl M, Ramharter J, Savarese F, Gerlach D, Marszalek JR et al (2021) BI-3406, a potent and selective SOS1-KRAS interaction inhibitor, is effective in KRAS-driven cancers through combined MEK inhibition. Cancer Discov 11(1):142\u2013157","journal-title":"Cancer Discov"},{"issue":"8","key":"12115_CR8","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1158\/2159-8290.CD-NB2019-073","volume":"9","author":"AMG 510","year":"2019","unstructured":"AMG 510 (2019) First to inhibit undruggable KRAS. Cancer Discov 9(8):988\u2013989","journal-title":"Cancer Discov"},{"issue":"18","key":"12115_CR9","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","volume":"82","author":"AV Sorokin","year":"2022","unstructured":"Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G et al (2022) Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6. Cancer Res 82(18):3335\u20133344","journal-title":"Cancer Res"},{"issue":"8","key":"12115_CR10","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.annonc.2021.03.206","volume":"32","author":"A Grothey","year":"2021","unstructured":"Grothey A, Fakih M, Tabernero J (2021) Management of BRAF-mutant metastatic colorectal cancer: a review of treatment options and evidence-based guidelines. Annals oncology: official J Eur Soc Med Oncol 32(8):959\u2013967","journal-title":"Annals oncology: official J Eur Soc Med Oncol"},{"issue":"4","key":"12115_CR11","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2159-8290.CD-17-1226","volume":"8","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Andr\u00e9 T, Atreya CE, Schellens JHM, Yoshino T, Bendell JC et al (2018) Combined BRAF, EGFR, and MEK inhibition in patients with BRAF(V600E)-mutant colorectal cancer. Cancer Discov 8(4):428\u2013443","journal-title":"Cancer Discov"},{"issue":"6","key":"12115_CR12","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40262-022-01129-y","volume":"61","author":"F Namour","year":"2022","unstructured":"Namour F, Anderson K, Nelson C, Tasset C (2022) Filgotinib: a clinical pharmacology review. Clin Pharmacokinet 61(6):819\u2013832","journal-title":"Clin Pharmacokinet"},{"issue":"18","key":"12115_CR13","first-page":"1987","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S, Keam SJ (2020) Filgotinib first approval drugs 80(18):1987\u20131997","journal-title":"First Approval Drugs"},{"issue":"8","key":"12115_CR14","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40261-021-01055-0","volume":"41","author":"ES Kim","year":"2021","unstructured":"Kim ES, Keam SJ (2021) Filgotinib in rheumatoid arthritis: a profile of its use. Clin Drug Investig 41(8):741\u2013749","journal-title":"Clin Drug Investig"},{"issue":"10292","key":"12115_CR15","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","volume":"397","author":"BG Feagan","year":"2021","unstructured":"Feagan BG, Danese S, Loftus EV Jr., Vermeire S, Schreiber S, Ritter T et al (2021) Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial. Lancet (London England) 397(10292):2372\u20132384","journal-title":"Lancet (London England)"},{"issue":"5","key":"12115_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/ecco-jcc\/jjab206","volume":"16","author":"F D\u2019Amico","year":"2022","unstructured":"D\u2019Amico F, Magro F, Peyrin-Biroulet L, Danese S (2022) Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohn\u2019s colitis 16(5):835\u2013844","journal-title":"J Crohn\u2019s colitis"},{"issue":"3","key":"12115_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1053\/j.gastro.2021.10.035","volume":"162","author":"SC Shah","year":"2022","unstructured":"Shah SC, Itzkowitz SH (2022) Colorectal cancer in inflammatory bowel disease: mechanisms and management. Gastroenterology 162(3):715\u201330e3","journal-title":"Gastroenterology"},{"issue":"2","key":"12115_CR18","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.canlet.2013.07.032","volume":"345","author":"G Rogler","year":"2014","unstructured":"Rogler G (2014) Chronic ulcerative colitis and colorectal cancer. Cancer Lett 345(2):235\u2013241","journal-title":"Cancer Lett"},{"key":"12115_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.bbacli.2015.11.002","volume":"5","author":"A Jurjus","year":"2016","unstructured":"Jurjus A, Eid A, Al Kattar S, Zeenny MN, Gerges-Geagea A, Haydar H et al (2016) Inflammatory bowel disease, colorectal cancer and type 2 diabetes mellitus: The links. BBA Clin 5:16\u201324","journal-title":"BBA Clin"},{"issue":"1","key":"12115_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12967-024-05251-2","volume":"22","author":"E Gharib","year":"2024","unstructured":"Gharib E, Rejali L, Piroozkhah M, Zonoobi E, Nasrabadi PN, Arabsorkhi Z et al (2024) IL-2RG as a possible immunotherapeutic target in CRC predicting poor prognosis and regulated by miR-7-5p and miR-26b-5p. J translational Med 22(1):439","journal-title":"J translational Med"},{"key":"12115_CR21","doi-asserted-by":"publisher","first-page":"1507621","DOI":"10.3389\/fcell.2024.1507621","volume":"12","author":"P Li","year":"2024","unstructured":"Li P, Huang D (2024) Targeting the JAK-STAT pathway in colorectal cancer: mechanisms, clinical implications, and therapeutic potential. Front cell Dev biology 12:1507621","journal-title":"Front cell Dev biology"},{"issue":"33","key":"12115_CR22","first-page":"e2310037","volume":"11","author":"Y Hong","year":"2024","unstructured":"Hong Y, Chen Q, Wang Z, Zhang Y, Li B, Guo H et al (2024) Targeting nuclear receptor coactivator SRC-1 prevents colorectal cancer immune escape by reducing transcription and protein stability of PD-L1. Adv Sci (Weinheim Baden-Wurttemberg Germany) 11(33):e2310037","journal-title":"Adv Sci (Weinheim Baden-Wurttemberg Germany)"},{"issue":"3","key":"12115_CR23","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.18632\/aging.202354","volume":"13","author":"C Li","year":"2021","unstructured":"Li C, Pan B, Liu X, Qin J, Wang X, He B et al (2021) Long intergenic non-coding RNA LINC00485 exerts tumor-suppressive activity by regulating miR-581\/EDEM1 axis in colorectal cancer. Aging 13(3):3866\u20133885","journal-title":"Aging"},{"issue":"1","key":"12115_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0003-2697(86)90314-3","volume":"159","author":"RJ Gillies","year":"1986","unstructured":"Gillies RJ, Didier N, Denton M (1986) Determination of cell number in monolayer cultures. Anal Biochem 159(1):109\u2013113","journal-title":"Anal Biochem"},{"issue":"9","key":"12115_CR25","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1073\/pnas.88.9.3671","volume":"88","author":"ST Smiley","year":"1991","unstructured":"Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW et al (1991) Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci USA 88(9):3671\u20133675","journal-title":"Proc Natl Acad Sci USA"},{"issue":"7","key":"12115_CR26","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1073\/pnas.0712168105","volume":"105","author":"A Salic","year":"2008","unstructured":"Salic A, Mitchison TJ (2008) A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci USA 105(7):2415\u20132420","journal-title":"Proc Natl Acad Sci USA"},{"issue":"8","key":"12115_CR27","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1007\/s00432-022-03981-8","volume":"148","author":"C Li","year":"2022","unstructured":"Li C, Pan B, Wang X, Liu X, Qin J, Gao T et al (2022) Upregulated LINC01088 facilitates malignant phenotypes and immune escape of colorectal cancer by regulating microRNAs\/G3BP1\/PD-L1 axis. J Cancer Res Clin Oncol 148(8):1965\u20131982","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"12115_CR28","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1593\/neo.07971","volume":"10","author":"H Xiong","year":"2008","unstructured":"Xiong H, Zhang ZG, Tian XQ, Sun DF, Liang QC, Zhang YJ et al (2008) Inhibition of JAK1, 2\/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia (New York NY) 10(3):287\u2013297","journal-title":"Neoplasia (New York NY)"},{"issue":"1","key":"12115_CR29","doi-asserted-by":"publisher","first-page":"56","DOI":"10.4149\/neo_2014_009","volume":"61","author":"HJ An","year":"2014","unstructured":"An HJ, Choi EK, Kim JS, Hong SW, Moon JH, Shin JS et al (2014) INCB018424 induces apoptotic cell death through the suppression of pJAK1 in human colon cancer cells. Neoplasma 61(1):56\u201362","journal-title":"Neoplasma"},{"issue":"9","key":"12115_CR30","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s43018-022-00431-9","volume":"3","author":"S Deng","year":"2022","unstructured":"Deng S, Wang C, Wang Y, Xu Y, Li X, Johnson NA et al (2022) Ectopic JAK-STAT activation enables the transition to a stem-like and multilineage state conferring AR-targeted therapy resistance. Nat cancer 3(9):1071\u20131087","journal-title":"Nat cancer"},{"issue":"2","key":"12115_CR31","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M (2023) Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discovery 22(2):127\u2013144","journal-title":"Nat Rev Drug Discovery"},{"key":"12115_CR32","doi-asserted-by":"crossref","unstructured":"Br\u00e1zda V, Fojta M (2019) The rich world of p53 DNA binding targets: the role of DNA Structure. Int J Mol Sci 20(22):5605","DOI":"10.3390\/ijms20225605"},{"issue":"1","key":"12115_CR33","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s12943-019-1029-8","volume":"18","author":"Y Gong","year":"2019","unstructured":"Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K et al (2019) The role of necroptosis in cancer biology and therapy. Mol Cancer 18(1):100","journal-title":"Mol Cancer"},{"key":"12115_CR34","doi-asserted-by":"crossref","unstructured":"Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ et al (2018) Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 10(436):eaan8292","DOI":"10.1126\/scitranslmed.aan8292"},{"key":"12115_CR35","doi-asserted-by":"crossref","unstructured":"Suboti\u010dki T, Mitrovi\u0107 Ajti\u0107 O, \u017divkovi\u0107 E, Dikli\u0107 M, \u0110iki\u0107 D, To\u0161i\u0107 M et al (2021) VEGF regulation of angiogenic factors via inflammatory signaling in myeloproliferative neoplasms. Int J Mol Sci. 22(13):6671","DOI":"10.3390\/ijms22136671"},{"issue":"5","key":"12115_CR36","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.molcel.2019.04.027","volume":"74","author":"D Cortez","year":"2019","unstructured":"Cortez D, Replication-Coupled DNA (2019) Repair Mol cell 74(5):866\u2013876","journal-title":"Repair Mol cell"},{"key":"12115_CR37","doi-asserted-by":"publisher","first-page":"101287","DOI":"10.1016\/j.drup.2025.101287","volume":"83","author":"H Zhu","year":"2025","unstructured":"Zhu H, Tian Y, Chen H, Qian Y, Li J, Niu D et al (2025) Targeting DNA damage response pathways in tumor drug resistance: Mechanisms, clinical implications, and future directions. Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother 83:101287","journal-title":"Drug Resist updates: reviews commentaries Antimicrob anticancer Chemother"},{"key":"12115_CR38","doi-asserted-by":"crossref","unstructured":"Reddig A, Voss L, Guttek K, Roggenbuck D, Feist E, Reinhold D (2021) Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage. J Clin Med. 10(7):1431","DOI":"10.3390\/jcm10071431"},{"key":"12115_CR39","doi-asserted-by":"crossref","unstructured":"Zhang H, Xu J, Long Y, Maimaitijiang A, Su Z, Li W et al (2024) Unraveling the Guardian: p53\u2019s Multifaceted Role in the DNA Damage Response and Tumor Treatment Strategies. Int J Mol Sci. 25(23):12928","DOI":"10.3390\/ijms252312928"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12115-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12115-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12115-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:11:57Z","timestamp":1782562317000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12115-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12115"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12115-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"25 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of the Second Affiliated Hospital of Xiamen Medical College (Approval No. 2024119). Written informed consent was obtained from all participants prior to sample collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"1014"}}